25 XP   0   0   10

Neurobo Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Neurobo Pharmaceuticals Inc together

PenkeI guess you are interested in Neurobo Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Neurobo Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Neurobo Pharmaceuticals Inc

I send you an email if I find something interesting about Neurobo Pharmaceuticals Inc.

Quick analysis of Neurobo Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Neurobo Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.28
Expected worth in 1 year
$5.71
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
$2.43
Return On Investment
70.2%

For what price can you sell your share?

Current Price per Share
$3.46
Expected price per share
$2.9 - $4.76
How sure are you?
50%

1. Valuation of Neurobo Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$3.46

Intrinsic Value Per Share

$-32.45 - $-38.70

Total Value Per Share

$-29.16 - $-35.41

2. Growth of Neurobo Pharmaceuticals Inc (5 min.)




Is Neurobo Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$16.6m$12.1m$8.8m42.3%

How much money is Neurobo Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$3.1m-$2m-$1m-33.2%
Net Profit Margin-33,212.5%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Neurobo Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#617 / 1019

Most Revenue
#719 / 1019

Most Profit
#358 / 1019

Most Efficient
#986 / 1019

What can you expect buying and holding a share of Neurobo Pharmaceuticals Inc? (5 min.)

Welcome investor! Neurobo Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Neurobo Pharmaceuticals Inc.

What can you expect buying and holding a share of Neurobo Pharmaceuticals Inc?

First you should know what it really means to hold a share of Neurobo Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Neurobo Pharmaceuticals Inc is $3.46. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neurobo Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neurobo Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.28. Based on the TTM, the Book Value Change Per Share is $0.61 per quarter. Based on the YOY, the Book Value Change Per Share is $0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neurobo Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.05-30.2%-0.49-14.2%-0.09-2.7%-0.54-15.7%-0.76-21.9%
Usd Book Value Change Per Share-0.96-27.8%0.6117.6%0.051.4%0.9427.2%0.102.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.96-27.8%0.6117.6%0.051.4%0.9427.2%0.102.9%
Usd Price Per Share3.70-1.33-3.95-3.88-4.75-
Price to Earnings Ratio-0.88--2.09--9.63--3.88--2.82-
Price-to-Total Gains Ratio-3.85--2.86--33.49--51.63--35.21-
Price to Book Ratio1.13-0.57-16.41-6.78-5.01-
Price-to-Total Gains Ratio-3.85--2.86--33.49--51.63--35.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.46
Number of shares289
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.610.94
Usd Total Gains Per Share0.610.94
Gains per Quarter (289 shares)175.53272.30
Gains per Year (289 shares)702.131,089.21
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10702692010891079
2014041394021782168
3021062096032683257
4028092798043574346
5035113500054465435
6042134202065356524
7049154904076247613
8056175606087148702
9063196308098039791
1007021701001089210880

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.033.00.00.0%0.033.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%11.022.00.033.3%11.022.00.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.033.00.0%0.00.033.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%11.022.00.033.3%11.022.00.033.3%

Fundamentals of Neurobo Pharmaceuticals Inc

About Neurobo Pharmaceuticals Inc

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 16:07:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Neurobo Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Neurobo Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -132,850.0% means that $-1,328.50 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is -132,850.0%. The company is making a huge loss. -2
  • The TTM is -33,212.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-132,850.0%TTM-33,212.5%-99,637.5%
TTM-33,212.5%YOY--33,212.5%
TTM-33,212.5%5Y-6,642.5%-26,570.0%
5Y-6,642.5%10Y-4,025.8%-2,616.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-132,850.0%-197.2%-132,652.8%
TTM-33,212.5%-210.4%-33,002.1%
YOY--279.3%+279.3%
5Y-6,642.5%-436.8%-6,205.7%
10Y-4,025.8%-599.3%-3,426.5%
1.1.2. Return on Assets

Shows how efficient Neurobo Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • -23.3% Return on Assets means that Neurobo Pharmaceuticals Inc generated $-0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is -23.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.3%TTM-12.2%-11.1%
TTM-12.2%YOY-23.3%+11.1%
TTM-12.2%5Y-57.9%+45.7%
5Y-57.9%10Y-49.4%-8.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.3%-13.6%-9.7%
TTM-12.2%-12.9%+0.7%
YOY-23.3%-11.9%-11.4%
5Y-57.9%-14.2%-43.7%
10Y-49.4%-16.2%-33.2%
1.1.3. Return on Equity

Shows how efficient Neurobo Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • -31.8% Return on Equity means Neurobo Pharmaceuticals Inc generated $-0.32 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is -31.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-31.8%TTM-16.4%-15.5%
TTM-16.4%YOY-27.6%+11.2%
TTM-16.4%5Y-71.3%+54.9%
5Y-71.3%10Y-59.3%-12.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-31.8%-17.0%-14.8%
TTM-16.4%-16.1%-0.3%
YOY-27.6%-15.4%-12.2%
5Y-71.3%-20.0%-51.3%
10Y-59.3%-21.1%-38.2%

1.2. Operating Efficiency of Neurobo Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Neurobo Pharmaceuticals Inc is operating .

  • Measures how much profit Neurobo Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -141,675.0% means the company generated $-1,416.75  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is -141,675.0%. The company is operating very inefficient. -2
  • The TTM is -35,418.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-141,675.0%TTM-35,418.8%-106,256.3%
TTM-35,418.8%YOY--35,418.8%
TTM-35,418.8%5Y-7,083.8%-28,335.0%
5Y-7,083.8%10Y-4,293.2%-2,790.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-141,675.0%-286.1%-141,388.9%
TTM-35,418.8%-224.4%-35,194.4%
YOY--288.4%+288.4%
5Y-7,083.8%-475.2%-6,608.6%
10Y-4,293.2%-624.7%-3,668.5%
1.2.2. Operating Ratio

Measures how efficient Neurobo Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1,416.75 means that the operating costs are $1,416.75 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 1,416.750. The company is inefficient in keeping operating costs low. -1
  • The TTM is 354.188. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1,416.750TTM354.188+1,062.563
TTM354.188YOY-+354.188
TTM354.1885Y70.838+283.350
5Y70.83810Y42.932+27.906
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1,416.7502.997+1,413.753
TTM354.1883.247+350.941
YOY-3.766-3.766
5Y70.8385.675+65.163
10Y42.9327.857+35.075

1.3. Liquidity of Neurobo Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Neurobo Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.78 means the company has $3.78 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 3.777. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.876. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.777TTM4.876-1.099
TTM4.876YOY6.111-1.235
TTM4.8765Y4.741+0.136
5Y4.74110Y4.573+0.168
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7773.930-0.153
TTM4.8764.251+0.625
YOY6.1115.436+0.675
5Y4.7416.045-1.304
10Y4.5736.363-1.790
1.3.2. Quick Ratio

Measures if Neurobo Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 3.76 means the company can pay off $3.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 3.764. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.811. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.764TTM4.811-1.047
TTM4.811YOY5.392-0.581
TTM4.8115Y4.425+0.386
5Y4.42510Y4.340+0.085
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7643.629+0.135
TTM4.8114.065+0.746
YOY5.3925.397-0.005
5Y4.4255.993-1.568
10Y4.3406.277-1.937

1.4. Solvency of Neurobo Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Neurobo Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Neurobo Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27 means that Neurobo Pharmaceuticals Inc assets are financed with 26.8% credit (debt) and the remaining percentage (100% - 26.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 0.268. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.234. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.268TTM0.234+0.033
TTM0.234YOY0.201+0.033
TTM0.2345Y0.309-0.074
5Y0.30910Y0.697-0.388
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2680.332-0.064
TTM0.2340.334-0.100
YOY0.2010.268-0.067
5Y0.3090.366-0.057
10Y0.6970.390+0.307
1.4.2. Debt to Equity Ratio

Measures if Neurobo Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 36.5% means that company has $0.37 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neurobo Pharmaceuticals Inc:

  • The MRQ is 0.365. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.321. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.365TTM0.321+0.044
TTM0.321YOY0.271+0.050
TTM0.3215Y0.338-0.017
5Y0.33810Y0.480-0.142
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3650.381-0.016
TTM0.3210.390-0.069
YOY0.2710.334-0.063
5Y0.3380.434-0.096
10Y0.4800.466+0.014

2. Market Valuation of Neurobo Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Neurobo Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Neurobo Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.88 means the investor is paying $-0.88 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neurobo Pharmaceuticals Inc:

  • The EOD is -0.827. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.884. Based on the earnings, the company is expensive. -2
  • The TTM is -2.092. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.827MRQ-0.884+0.057
MRQ-0.884TTM-2.092+1.208
TTM-2.092YOY-9.633+7.542
TTM-2.0925Y-3.882+1.790
5Y-3.88210Y-2.823-1.058
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.827-2.315+1.488
MRQ-0.884-2.560+1.676
TTM-2.092-2.664+0.572
YOY-9.633-4.122-5.511
5Y-3.882-6.258+2.376
10Y-2.823-6.108+3.285
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Neurobo Pharmaceuticals Inc:

  • The EOD is -1.292. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.380. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.938. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.292MRQ-1.380+0.088
MRQ-1.380TTM-0.938-0.442
TTM-0.938YOY-10.888+9.950
TTM-0.9385Y-5.998+5.059
5Y-5.99810Y-4.173-1.825
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.292-3.067+1.775
MRQ-1.380-3.251+1.871
TTM-0.938-3.545+2.607
YOY-10.888-5.595-5.293
5Y-5.998-8.315+2.317
10Y-4.173-8.708+4.535
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Neurobo Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.13 means the investor is paying $1.13 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Neurobo Pharmaceuticals Inc:

  • The EOD is 1.053. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.126. Based on the equity, the company is underpriced. +1
  • The TTM is 0.567. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.053MRQ1.126-0.072
MRQ1.126TTM0.567+0.559
TTM0.567YOY16.412-15.846
TTM0.5675Y6.777-6.210
5Y6.77710Y5.008+1.769
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.0531.905-0.852
MRQ1.1262.111-0.985
TTM0.5672.095-1.528
YOY16.4122.836+13.576
5Y6.7773.443+3.334
10Y5.0083.794+1.214
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Neurobo Pharmaceuticals Inc.

3.1. Institutions holding Neurobo Pharmaceuticals Inc

Institutions are holding 1.899% of the shares of Neurobo Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Citadel Advisors Llc0.1182046374463740
2023-12-31Hudson Bay Capital Management LP0.84930.00141666416660
2023-12-31Geode Capital Management, LLC0.3533017332-2-0.0115
2023-12-31BlackRock Inc0.107505274-1-0.019
2023-12-31Tower Research Capital LLC0.0440.0001215961639.9222
2023-12-31Wells Fargo & Co0.000502528.6957
2023-12-31Morgan Stanley - Brokerage Accounts0.0005025250
2023-12-31Comerica Bank002-1-33.3333
2023-12-31Bank of America Corp00100
2023-12-31State Street Corporation000-2835-100
2023-12-31UBS Group AG000-18-100
2023-12-31Vanguard Group Inc000-8699-100
2023-09-30Two Sigma Investments LLC000-12487-100
2023-12-31Virtu Financial LLC000-4034-100
2023-12-31TWO SIGMA SECURITIES, LLC000-5371-100
Total 1.47330.0011112858+55235+48.9%

3.2. Funds holding Neurobo Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30BlackRock Extended Mkt Composite0.10580.00014151300
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.57110.00022802018282187.7388
2024-01-31Fidelity Extended Market Index0.34970.00021715700
2023-12-31BlackRock Extended Equity Market K0.09230.00014527-9-0.1984
2024-01-31Fidelity Series Total Market Index0.06870337133710
2023-12-31Extended Equity Market Fund M0.01140.0001560275.0657
2024-01-31DFA US Small Cap I0.0072035500
2024-02-29Vanguard U.S. Eq Idx £ Acc0.0038018400
2024-01-31Fidelity Nasdaq Composite Index0.0023011300
2024-02-29Dimensional US Small Cap ETF0.00209800
2024-01-31DFA US Targeted Value I0.001909100
2023-12-31SSgA U.S. Extended Market Index Class I0.000904400
2024-02-29State St US Extended Mkt Indx NL Cl C0.000904400
2024-01-31Spartan Extended Market Index Pool E0.000904300
2024-02-29Dimensional US Targeted Value ETF0.000703200
2023-12-31NT Quality SCC US Fund - L0.000402200
2023-12-31NT Quality Small Cap Core0.000402200
2023-12-31NT Ext Equity Mkt Idx Fd - L0.000402100
2023-12-31Northern Trust Extended Eq Market Idx0.000402100
2023-12-31SSgA U.S. Total Market Index Strategy0.000301300
Total 1.22150.000796251+21671+22.5%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Neurobo Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.9610.607-258%0.050-2021%0.942-202%0.100-1066%
Book Value Per Share--3.2853.316-1%0.464+608%1.345+144%1.099+199%
Current Ratio--3.7774.876-23%6.111-38%4.741-20%4.573-17%
Debt To Asset Ratio--0.2680.234+14%0.201+33%0.309-13%0.697-62%
Debt To Equity Ratio--0.3650.321+14%0.271+35%0.338+8%0.480-24%
Dividend Per Share----0%-0%-0%-0%
Eps---1.046-0.493-53%-0.094-91%-0.542-48%-0.757-28%
Free Cash Flow Per Share---0.670-0.432-35%-0.111-83%-0.302-55%-0.566-15%
Free Cash Flow To Equity Per Share---0.670-0.437-35%0.169-497%0.219-406%0.229-392%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---38.696--------
Intrinsic Value_10Y_min---32.446--------
Intrinsic Value_1Y_max---1.338--------
Intrinsic Value_1Y_min---1.313--------
Intrinsic Value_3Y_max---5.957--------
Intrinsic Value_3Y_min---5.648--------
Intrinsic Value_5Y_max---12.908--------
Intrinsic Value_5Y_min---11.814--------
Market Cap16974863.800-11%18779972.53910675628.936+76%104842934.375-82%50566013.020-63%42401957.050-56%
Net Profit Margin---1328.500-332.125-75%--100%-66.425-95%-40.258-97%
Operating Margin---1416.750-354.188-75%--100%-70.838-95%-42.932-97%
Operating Ratio--1416.750354.188+300%-+100%70.838+1900%42.932+3200%
Pb Ratio1.053-7%1.1260.567+99%16.412-93%6.777-83%5.008-78%
Pe Ratio-0.827+6%-0.884-2.092+137%-9.633+990%-3.882+339%-2.823+220%
Price Per Share3.460-7%3.6971.330+178%3.948-6%3.885-5%4.751-22%
Price To Free Cash Flow Ratio-1.292+6%-1.380-0.938-32%-10.888+689%-5.998+335%-4.173+202%
Price To Total Gains Ratio-3.600+6%-3.847-2.864-26%-33.487+770%-51.631+1242%-35.213+815%
Quick Ratio--3.7644.811-22%5.392-30%4.425-15%4.340-13%
Return On Assets---0.233-0.122-48%-0.2330%-0.579+148%-0.494+112%
Return On Equity---0.318-0.164-49%-0.276-13%-0.713+124%-0.593+86%
Total Gains Per Share---0.9610.607-258%0.050-2021%0.942-202%0.100-1066%
Usd Book Value--16685000.00020984750.000-20%12112250.000+38%11206250.000+49%8185272.727+104%
Usd Book Value Change Per Share---0.9610.607-258%0.050-2021%0.942-202%0.100-1066%
Usd Book Value Per Share--3.2853.316-1%0.464+608%1.345+144%1.099+199%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.046-0.493-53%-0.094-91%-0.542-48%-0.757-28%
Usd Free Cash Flow---3402000.000-2712250.000-20%-2928000.000-14%-2596250.000-24%-3455636.364+2%
Usd Free Cash Flow Per Share---0.670-0.432-35%-0.111-83%-0.302-55%-0.566-15%
Usd Free Cash Flow To Equity Per Share---0.670-0.437-35%0.169-497%0.219-406%0.229-392%
Usd Market Cap16974863.800-11%18779972.53910675628.936+76%104842934.375-82%50566013.020-63%42401957.050-56%
Usd Price Per Share3.460-7%3.6971.330+178%3.948-6%3.885-5%4.751-22%
Usd Profit---5314000.000-3138500.000-41%-2097500.000-61%-5678600.000+7%-5690303.030+7%
Usd Revenue--4000.0001000.000+300%-+100%200.000+1900%121.212+3200%
Usd Total Gains Per Share---0.9610.607-258%0.050-2021%0.942-202%0.100-1066%
 EOD+3 -5MRQTTM+5 -28YOY+7 -265Y+11 -2210Y+13 -20

4.2. Fundamental Score

Let's check the fundamental score of Neurobo Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.827
Price to Book Ratio (EOD)Between0-11.053
Net Profit Margin (MRQ)Greater than0-1,328.500
Operating Margin (MRQ)Greater than0-1,416.750
Quick Ratio (MRQ)Greater than13.764
Current Ratio (MRQ)Greater than13.777
Debt to Asset Ratio (MRQ)Less than10.268
Debt to Equity Ratio (MRQ)Less than10.365
Return on Equity (MRQ)Greater than0.15-0.318
Return on Assets (MRQ)Greater than0.05-0.233
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Neurobo Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.508
Ma 20Greater thanMa 503.942
Ma 50Greater thanMa 1004.653
Ma 100Greater thanMa 2004.168
OpenGreater thanClose3.690
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets22,781
Total Liabilities6,096
Total Stockholder Equity16,685
 As reported
Total Liabilities 6,096
Total Stockholder Equity+ 16,685
Total Assets = 22,781

Assets

Total Assets22,781
Total Current Assets22,512
Long-term Assets269
Total Current Assets
Cash And Cash Equivalents 22,435
Other Current Assets 77
Total Current Assets  (as reported)22,512
Total Current Assets  (calculated)22,512
+/-0
Long-term Assets
Property Plant Equipment 248
Long-term Assets Other 21
Long-term Assets  (as reported)269
Long-term Assets  (calculated)269
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,960
Long-term Liabilities136
Total Stockholder Equity16,685
Total Current Liabilities
Short-term Debt 67
Accounts payable 821
Other Current Liabilities 5,072
Total Current Liabilities  (as reported)5,960
Total Current Liabilities  (calculated)5,960
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt136
Long-term Liabilities  (as reported)136
Long-term Liabilities  (calculated)136
+/-0
Total Stockholder Equity
Common Stock5
Retained Earnings -108,265
Other Stockholders Equity 124,945
Total Stockholder Equity (as reported)16,685
Total Stockholder Equity (calculated)16,685
+/-0
Other
Capital Stock5
Cash and Short Term Investments 22,435
Common Stock Shares Outstanding 5,080
Liabilities and Stockholders Equity 22,781
Net Debt -22,232
Net Invested Capital 16,685
Net Working Capital 16,552
Property Plant and Equipment Gross 282
Short Long Term Debt Total 203



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
> Total Assets 
0
0
0
4,500
1,658
6,726
28,924
24,754
29,842
23,004
26,211
19,017
34,837
28,798
24,870
19,694
6,158
4,014
2,048
14,468
11,535
15,552
13,198
10,968
10,838
10,719
8,077
16,799
13,461
10,082
7,557
33,534
31,488
29,179
26,425
22,781
22,78126,42529,17931,48833,5347,55710,08213,46116,7998,07710,71910,83810,96813,19815,55211,53514,4682,0484,0146,15819,69424,87028,79834,83719,01726,21123,00429,84224,75428,9246,7261,6584,500000
   > Total Current Assets 
0
0
0
3,643
1,653
6,718
28,916
24,746
29,834
22,974
26,203
19,009
34,829
28,798
24,862
18,954
6,106
3,988
2,048
14,118
11,211
15,243
12,898
10,683
10,683
10,468
7,844
16,584
13,264
10,077
7,554
33,532
31,483
29,174
26,145
22,512
22,51226,14529,17431,48333,5327,55410,07713,26416,5847,84410,46810,68310,68312,89815,24311,21114,1182,0483,9886,10618,95424,86228,79834,82919,00926,20322,97429,83424,74628,9166,7181,6533,643000
       Cash And Cash Equivalents 
0
0
0
3,620
1,629
4,826
28,369
24,033
29,282
22,491
25,340
18,473
34,461
28,039
23,806
18,954
5,510
3,643
1,855
13,908
9,799
14,298
12,353
10,089
10,089
9,513
6,984
16,387
11,557
8,849
6,356
33,364
30,813
28,688
25,837
22,435
22,43525,83728,68830,81333,3646,3568,84911,55716,3876,9849,51310,08910,08912,35314,2989,79913,9081,8553,6435,51018,95423,80628,03934,46118,47325,34022,49129,28224,03328,3694,8261,6293,620000
       Other Current Assets 
0
0
0
23
24
1,730
547
713
552
483
863
25
68
759
14
17
68
78
38
42
65
37
34
594
594
955
860
197
1,707
1,228
1,198
168
670
486
308
77
773084866701681,1981,2281,70719786095559459434376542387868171475968258634835527135471,7302423000
   > Long-term Assets 
0
0
0
857
5
8
8
8
8
30
8
8
8
8
8
740
52
26
0
350
324
309
300
285
155
251
233
215
197
5
3
2
5
5
280
269
2692805523519721523325115528530030932435002652740888883088885857000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
52
26
237
350
324
277
267
155
155
251
233
215
197
5
3
2
5
5
259
248
2482595523519721523325115515526727732435023726523300000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
-8
9
9
8
8
32
0
0
32
33
0
130
0
0
0
0
0
0
0
0
0
0
0
000000000001300333200328899-80000000000000
> Total Liabilities 
0
0
0
16,880
2,252
22,681
1,936
4,122
4,545
5,274
16,262
15,076
14,020
13,750
14,017
96,031
1,712
2,050
3,073
2,176
3,795
3,214
3,692
3,765
3,765
1,241
1,952
2,202
1,533
1,249
1,619
11,784
10,980
3,983
4,875
6,096
6,0964,8753,98310,98011,7841,6191,2491,5332,2021,9521,2413,7653,7653,6923,2143,7952,1763,0732,0501,71296,03114,01713,75014,02015,07616,2625,2744,5454,1221,93622,6812,25216,880000
   > Total Current Liabilities 
0
0
0
8,927
2,252
14,429
1,936
4,121
4,543
5,272
6,295
6,390
6,257
6,215
7,617
9,437
1,712
2,050
3,073
2,082
3,706
3,132
3,615
3,695
3,695
1,183
1,901
2,157
1,496
1,249
1,619
11,784
10,980
3,983
4,722
5,960
5,9604,7223,98310,98011,7841,6191,2491,4962,1571,9011,1833,6953,6953,6153,1323,7062,0823,0732,0501,7129,4377,6176,2156,2576,3906,2955,2724,5434,1211,93614,4292,2528,927000
       Short-term Debt 
0
0
0
6,424
0
11,089
0
0
0
0
0
1,355
2,355
2,652
3,681
9,437
44
18
0
22
22
23
23
0
24
25
26
26
27
0
0
0
0
0
65
67
6765000002726262524023232222018449,4373,6812,6522,3551,3550000011,08906,424000
       Accounts payable 
0
0
0
531
224
642
1,257
2,008
3,541
3,464
4,332
4,025
2,848
2,569
2,351
2,044
1,234
1,668
2,677
638
1,273
1,683
1,101
3,671
2,575
347
953
830
776
664
1,075
708
1,119
967
1,981
821
8211,9819671,1197081,0756647768309533472,5753,6711,1011,6831,2736382,6771,6681,2342,0442,3512,5692,8484,0254,3323,4643,5412,0081,257642224531000
       Other Current Liabilities 
0
0
0
345
2,028
243
679
2,113
1,002
1,808
1,963
1,010
1,054
994
1,585
438
478
382
396
1,444
2,433
1,449
2,514
94
1,120
811
922
1,301
693
585
544
11,076
9,861
3,016
1,062
5,072
5,0721,0623,0169,86111,0765445856931,3019228111,120942,5141,4492,4331,4443963824784381,5859941,0541,0101,9631,8081,0022,1136792432,028345000
   > Long-term Liabilities 
0
0
0
7,953
0
8,252
0
1
2
2
9,967
8,686
7,763
7,543
6,400
86,594
1
0
0
94
89
82
77
70
70
58
51
45
37
664
1,075
708
1,119
0
153
136
13615301,1197081,0756643745515870707782899400186,5946,4007,5437,7638,6869,96722108,25207,953000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,398
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000006,39800000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
23
35
35
42
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000423535232300000000000000
> Total Stockholder Equity
0
0
0
-12,380
-594
-15,955
26,988
20,632
25,297
17,730
9,949
3,941
20,817
15,048
10,853
-76,337
4,446
1,964
-1,025
12,292
7,740
12,338
9,506
7,203
7,203
9,478
6,125
14,597
11,928
8,833
5,938
21,750
20,508
25,196
21,550
16,685
16,68521,55025,19620,50821,7505,9388,83311,92814,5976,1259,4787,2037,2039,50612,3387,74012,292-1,0251,9644,446-76,33710,85315,04820,8173,9419,94917,73025,29720,63226,988-15,955-594-12,380000
   Common Stock
0
0
0
12
12
12
17
17
18
18
18
18
22
22
22
22
22
22
23
16
16
17
17
20
20
22
22
27
27
27
1
25
27
38
38
5
5383827251272727222220201717161623222222222222181818181717121212000
   Retained Earnings Total Equity0000000000-73,789-69,868-66,54400000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-16,504
-28,924
-24,754
0
0
0
0
0
0
0
0
0
0
0
12
-22
-16
-3
14
14
3
4
4
3
0
0
0
0
0
0
0
000000034431414-3-16-221200000000000-24,754-28,924-16,50400000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
91,286
91,863
92,336
92,774
93,214
49,130
49,342
0
0
73,713
82,990
83,242
0
0
0
0
0
0
0
0
0
0
000000000083,24282,99073,7130049,34249,13093,21492,77492,33691,86391,28600000000000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
13,929
8,252
46,816
47,674
59,834
62,769
63,659
64,397
88,493
89,402
91,286
7,752
92,336
92,774
93,214
49,159
49,348
56,341
56,574
14
7,155
83,242
83,349
96,394
96,601
96,812
97,056
117,520
118,880
124,291
124,463
124,945
124,945124,463124,291118,880117,52097,05696,81296,60196,39483,34983,2427,1551456,57456,34149,34849,15993,21492,77492,3367,75291,28689,40288,49364,39763,65962,76959,83447,67446,8168,25213,9290000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue7
Cost of Revenue-7
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-15,879
Operating Income-15,886-15,879
 
Operating Expense (+$)
Research Development9,151
Selling General Administrative6,728
Selling And Marketing Expenses0
Operating Expense15,87915,879
 
Net Interest Income (+$)
Interest Income162
Interest Expense-0
Other Finance Cost-2,191
Net Interest Income-2,029
 
Pretax Income (+$)
Operating Income-15,886
Net Interest Income-2,029
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-12,470-19,302
EBIT - interestExpense = -15,886
-12,470
-12,470
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-15,886-12,470
Earnings Before Interest and Taxes (EBITDA)-15,879
 
After tax Income (+$)
Income Before Tax-12,470
Tax Provision-0
Net Income From Continuing Ops-11,832-12,470
Net Income-12,470
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses15,886
Total Other Income/Expenses Net3,4162,029
 

Technical Analysis of Neurobo Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neurobo Pharmaceuticals Inc. The general trend of Neurobo Pharmaceuticals Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neurobo Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Neurobo Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.11 < 4.73 < 4.76.

The bearish price targets are: 3.04 > 3.04 > 2.9.

Tweet this
Neurobo Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Neurobo Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Neurobo Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Neurobo Pharmaceuticals Inc. The current macd is -0.33291801.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Neurobo Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Neurobo Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Neurobo Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Neurobo Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartNeurobo Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Neurobo Pharmaceuticals Inc. The current adx is 22.82.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Neurobo Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Neurobo Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Neurobo Pharmaceuticals Inc. The current sar is 3.9376.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Neurobo Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Neurobo Pharmaceuticals Inc. The current rsi is 33.51. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Neurobo Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartNeurobo Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Neurobo Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neurobo Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Neurobo Pharmaceuticals Inc Daily Stochastic Oscillator ChartNeurobo Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Neurobo Pharmaceuticals Inc. The current cci is -97.19891402.

Neurobo Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartNeurobo Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Neurobo Pharmaceuticals Inc. The current cmo is -43.38290903.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Neurobo Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartNeurobo Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Neurobo Pharmaceuticals Inc. The current willr is -87.73584906.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Neurobo Pharmaceuticals Inc Daily Williams %R ChartNeurobo Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Neurobo Pharmaceuticals Inc.

Neurobo Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Neurobo Pharmaceuticals Inc. The current atr is 0.32614851.

Neurobo Pharmaceuticals Inc Daily Average True Range (ATR) ChartNeurobo Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Neurobo Pharmaceuticals Inc. The current obv is 80,921,254.

Neurobo Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartNeurobo Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Neurobo Pharmaceuticals Inc. The current mfi is 28.47.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Neurobo Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartNeurobo Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Neurobo Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-10MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Neurobo Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Neurobo Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.508
Ma 20Greater thanMa 503.942
Ma 50Greater thanMa 1004.653
Ma 100Greater thanMa 2004.168
OpenGreater thanClose3.690
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Neurobo Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Neurobo Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neurobo Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Neurobo Pharmaceuticals Inc

I send you an email if I find something interesting about Neurobo Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Neurobo Pharmaceuticals Inc.

Receive notifications about Neurobo Pharmaceuticals Inc in your mailbox!